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Dual Role of 1L-12 in Early and Late Stages of Murine 
Collagen Type II Arthritis1
Leo A. B, Joosten, Erik Lubberts, Monique M. A. Helsen, and Wim B. van den Berg
IL-12 can promote Th1 responses, and early administration of IL-12 during immunization was shown to enhance expression of 
autoimmune collagen-induced arthritis (CIA). We now studied the impact of IL-12 at the stage of disease expression and during 
established CIA in DBA-1 mice. Accelerated onset and enhanced severity were provoked when i.p. injections of 100 ng of 
murine IL-12 (mIL-12) were given around the time of arthritis onset. Moreover, the onset of CIA could be ameliorated with 
anti-mIL-12 Abs, indicating that IL-12 is a pivotal mediator in the expression of CIA. In addition, the effect of anti-mIL-12 
treatment was analyzed in established CIA. Continued treatment did not suppress established arthritis. Instead, these mice 
showed an impressive exacerbation of arthritis shortly after cessation of anti-mIL-12 treatment, indicative of impairment of 
endogenous control. Exaggerated disease was characterized by massive granulocyte influx and enhanced expression of 1L-1/3 
and TNF-a mRNA in the synovial tissue. Subsequently, we treated established collagen arthritis with recombinant mlL-12 for 
7 days. Profound suppression of the arthritis score was noted, including reduced influx of cells and diminished cartilage damage. 
Tenfold enhanced levels of IL-10 were detected in sera of mIL-12-treated mice, and up-regulated mRNA levels of IL-10, IFN-y, 
and IL-12 were measured in synovial tissue. Finally, the anti-inflammatory effect of IL-12 on CIA could be reversed by coad­
ministration of anti-lL-10 Abs. This study indicates that IL-12 has a stimulatory role in early arthritis expression, whereas it has
a suppressive role in the established phase of collagen arthritis.
I L-12 is a pleiotropic cytokine that is produced by APCs, macrophages, and B cells, and it promotes the growth of activated T cells and NK cells (1-4). IL-12 selectively gen­
erates the development of naive T cells into Thl cells and stimu­
lates IFN-y secretion by differentiated Thl cells (5-7). IL-12 is 
efficiently induced in macrophages upon stimulation with LPS, 
several bacteria, and intracellular parasites (8-10). In LPS-induced 
lethal shock and generalized Shwartzman reaction, IL-12 plays a 
crucial role through the major induction of IFN-y and TNF-a (11, 
12). In general, IL-12 is considered to be a principal protective 
factor in bacterial infections, where it bridges innate resistance and 
Ag-specific immunity (13). On the other hand, IL-12 may unmask 
Thl-dependent autoimmune reactions and may be a crucial inter­
mediate in the often-suggested link between bacterial infections 
and expression of autoimmune diseases (14). On the contrary, it 
controls excessive tissue pathology in allergy and parasitic infec­
tions by suppression of the Th2 response (15). Production of IL-12 
by activated macrophages is enhanced by IFN-y and is suppressed 
by IL-4 and IL-10 (16). More recently, it was demonstrated that 
IL-12 itself is an strong inducer of IL-10 production of T cells and 
macrophages in vitro, potentially providing an important negative 
feedback mechanism to prevent excessive activation and tissue 
pathology (17-21).
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Collagen-induced arthritis (CIA)" is a widely accepted experi­
mental model of polyarthritis. It can be induced in susceptible 
strains of mice and rats by immunization with heterologous type II 
collagen (CII), the major component of articular cartilage, and dis­
plays histopathologic features in common with human rheumatoid 
arthritis (RA) (22-24). The arthritis is dependent on the generation 
of a combination of anti-CII-Th 1 cellular immunity and the pro­
duction of anti-CII Abs, and full expression is best achieved upon 
immunization with CII in CFA. The Abs are essential elements in 
the onset of the arthritis. Complement-activating Abs bind to CII 
at the cartilage surface, with signs of acute inflammation, mild 
tissue damage, and further release of CII from the cartilage. Chro- 
nicity is then sustained by a T cell reaction in the synovial tissue. 
The monokines IL-1 and TNF enhance the autoimmune response 
to CII and exacerbate the arthritis (25). Furthermore, neutralization 
of IL-1 with anti-IL-1 Abs or IL-IRa even suppressed fully estab­
lished arthritis and ameliorated cartilage pathology, whereas 
TNF-a neutralization was less effective at that late, destructive 
stage (26-28). Recently, we demonstrated that expression of CIA 
is under stringent control of IL-4 and IL-10, in particular. Treat­
ment with anti-IL-4/anti-IL-10 shortly before the onset of CIA 
accelerated disease expression. Moreover, IL-4/IL-10 treatment of 
established CIA resulted in clear suppression of the arthritis and 
prevented cartilage destruction (29).
The first studies of IL-12 in collagen arthritis were focused on 
early treatment and skewing of CII autoimmunity. IL-12 can re­
place mycobacteria in the immunization protocol and causes se­
vere arthritis in DBA/1 mice when coadministered for 5 days with 
CII in ICF (30). A strongly enhanced anti-CII immunity was 
found. In contrast, high doses of IL-12 given to mice immunized
3 Abbreviations used in this paper: CIA, collagen-induced arthritis; CII, type II 
collagen; RA, rheumatoid arthritis; IL-1Ra, IL-1 receptor antagonist; rmlL-12, re­
combinant murine interleukin-12; PO, peroxidase; GAPDH, glycéraldéhyde 3- 
phosphate dehydrogenase.
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with CII in CFA were shown to inhibit the development of arthri­
tis, and this was associated with reduced anti-CII Ab levels (31). In 
the present study we focused on the potential role of IL-12 at the 
onset of arthritis, around day 28 after primary and booster immu­
nizations with CII on days 0 and 21. At that stage the mice already 
display anti-CII T cell immunity and high anti-CII Ab titers. Stud­
ies include in vivo treatment with either rmIL-12 or neutralizing 
anti-IL-12 Abs from day 28, and we are the first to demonstrate 
that such IL-12 treatment can accelerate arthritis expression, 
whereas anti-IL-12 Abs were shown to prevent arthritis onset. The 
most striking observation was the fact that anti-IL-12 treatment 
was without effect when started in fully established CIA on day 35, 
yet caused impressive exacerbation shortly after cessation of anti- 
IL-12 treatment, indicative of impairment of endogenous control. 
Further studies with late IL-12 treatment and neutralization with 
anti-IL~10 revealed impressive IL-12-mediated IL-10 generation 
and suggest that IL-12 has a stimulatory role in arthritis onset, yet 
a controlling role in the established stage of collagen arthritis. This 
suggests the need for subtle tuning of IL-12-directed therapy in 
human arthritis.
Materials and Methods
Animals
Male DBA-1 Lac/J mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Male DBA- 1/Bom mice were purchased from Bomholdgärd 
(Ry, Denmark). The mice were housed in filler-top cages, and water and 
food were provided ad libitum. The mice were immunized between 9 and 
10 wk of age.
Materials
CFA and Mycobacterium tuberculosis (strain H37Ra) were obtained from 
Difco Laboratories (Detroit, MI). LPS (Escherichia coli., 0111:84), 
ethidium bromide, rat Igs, sheep Igs, and BSA were purchased from Sigma 
Chemical Co. (St. Louis, MO). Taq DNA polymerase, 100-bp DNA  
marker, TRlzol reagent, and agarose were obtained from Life Technologies 
(Breda, The Netherlands).
Goat anti-murine Ig-peroxidase (PO), goat anti-murine IgGl-PO, and 
goat anti-murine IgG2a-PO were obtained from Southern Biotechnology 
Associates, Inc. (Birmingham, AL). GAPDH, IL-lß, IL-IRa, IL-4, IL-10, 
IL-12, IFN-y, TGF-/3, and TNF-a primers were purchased from Eurogen- 
tec (Seraing, Belgium). Recombinant murine IL-12 (3 X 106 U/mg) and 
purified sheep anti-murine IL-12 IgG were provided by Dr. S. Wolf, Ge­
netics Institute, Inc. (Cambridge, MA). Murine IL-10 ELISA kits were 
obtained from R&D Systems Europe Ltd. (Abingdon, U.K.). The cyto- 
screen murine IFN-y ELISA was purchased from BioSource (Camarillo, 
CA). Hybridoma cells (JES5-2A5) producing rat anti-murine IL-10 were 
obtained from American Type Culture Collection (Rockville, MD).
Collagen preparation
Articular cartilage was obtained from meta-carpophalangeal joints o f 1- to 
2-yr-old cows. Bovine CII was prepared according to the method of Miller 
and Rhodes. Collagen was resolved in 0.05 M acetic acid (10 mg/ml) and 
stored at -7 0 ° C  (26).
Immunization
Bovine CII was diluted with 0,05 M acetic acid to a concentration of 2 
mg/ml and was emulsified in equal volumes of CFA (2 mg/ml MT H37Ra). 
The mice were immunized intradermally at the base of the tail with 100 /xl 
of emulsion (100 jug of collagen). On day 21 the animals were boosted with 
an i.p. injection of 100 fig o f CII dissolved in PBS.
Acceleration o f collagen-induced arthritis
When DBA-1 Lac/J mice were immunized with CII and boosted on day 21, 
a gradual onset o f collagen arthritis was noted from day 28. At this point 
mice were visually scored for having collagen-induced arthritis. In general, 
arthritis incidence ranged from 10 to 30% of these animals. Mice without 
clear macroscopic signs of arthritis were selected at this stage, and the 
onset of arthritis was accelerated by a single i.p. injection of 40 /xg of LPS 
(27, 32). This resulted in the onset of CIA within 3 days, and on day 35 
full-blown expression of arthritis was noted in the paws of >95% of the 
animals. The histopathology in knee and ankle joints was comparable in
accelerated CIA and classic CIA. As described previously, administration 
of 40 jug of LPS to nonimmunized D B A -1 Lac/J mice or to mice immu­
nized with a nonarthritogenic Ag did not result in any macroscopic or 
histologic abnormalities (33).
Immunization of DBA-1/Bom mice resulted in high disease expression 
of 80 to 90% around day 28. Therefore, LPS acceleration was not neces­
sary in these animals.
Assessment o f  arthritis
Mice were examined for visual appearance of arthritis in peripheral joints, 
and scores for severity were given (arthritis score) as previously described 
(26-29). Mice were considered arthritic when significant changes in red­
ness and/or swelling were noted in digits or in other parts of the paws. At 
later time points ankylosis was also included in the arthritis score. Clinical 
severity of arthritis was graded on a scale of 0 to 2 for each paw, according 
to changes in redness and swelling: 0 =  no changes; 0.5 = significant 
changes; 1.0 =  moderate changes; 1.5 =  marked changes; and 2.0 =  
maximal swelling and redness, and later ankylosis. Arthritis score (mean ±  
SD) was expressed as the cumulative value for all paws, with a maximum 
of 8. More than 90% of the animals that expressed CIA in a particular ankle 
joint expressed arthritis in the knee joint of the same leg.
Treatment o f  CIA with miL-12, anti-mIL-12, or anti-mlL-10 
Abs
To evaluate the effect of mIL-12 on the onset of CIA, DBA-1 Lac/J mice 
without signs of arthritis on day 28 were treated for 5 days with 100 ng of  
mIL-12 or BSA as a control. The role of endogenous IL-12 during LPS 
acceleration of DBA-1 Lac/J mice was studied by anti-mIL-12 treatment. 
Two hundred micrograms of purified sheep anti-murine IL-12 Abs (34) or 
sheep Igs were injected i,p„ starting 2 h before LPS injection on the days 
indicated in Results, DBA-1 Bom mice with established CIA on day 35 
were selected and divided into groups of at least 10 mice with similar 
arthritis scores. Thereafter, mice were treated daily with 100 ng of mIL-12, 
starting on day 35 up to day 42, Anti-mIL-12 treatment of DBA-1 Bom  
mice with full-blown CIA was given i.p, on the days indicated in Results. 
To investigate whether the IL-10 was involved in IL-12 -mediated suppres­
sion of full-blown C)A, mIL-1.2 (100 ng/day) and anti-mIL-10 (0.75 mg of  
JES5-2A5) (29, 35) were injected. As a control we injected 0.75 mg of rat 
Igs and 100 ng of BSA i.p,
RNA isolation
Mice were killed by cervical dislocation, immediately followed by dis­
section of the patella with adjacent synovium (36, 37), Two synovium  
biopsies with a diameter of 3 mm were punched out of each patella, 
using a biopsy punch (Stiefel, Wachtersbach, Germany): one from the 
lateral and one from the medial side, Six patella specimens per exper­
imental group were taken, and three lateral and three medial biopsies 
were pooled to yield two samples per group. The synovium samples 
were immediately frozen in liquid nitrogen. Synovium biopsies were 
ground to powder using a microdismembrator II (B. Braun, Melsungen, 
Germany). Total RNA was extracted in 1 ml of TRlzol reagent, an 
improved single step RNA isolation method based on the method de­
scribed by Chomczynski and Sacchi (37, 38).
PCR amplifica tion
One microgram of synovial RNA was used for reverse transcriptase (RT)- 
PCR. mRNA was reverse transcribed to cDNA using oligo(dT) primers, 
and 1 /20th of the cDNA was used in one PCR amplification. PCR was 
performed at a final concentration of 200 pM  dNTPs, 0.1 /xM o f  each 
primer, and 1 U of Taq polymerase (Life Technologies) in standard PCR 
buffer. The mixture was overlaid with mineral oil and amplified in a ther­
mo eye 1er (Omnigene, Hybaid Ltd., Teddington, U.K.). Message for 
GAPDH, IL-1, IL-1 Ra. IL-4, IL-10, IL-12, IFN-y, TGF-/3, and T N F-a was 
amplified using primers described previously (27, 39). Samples o f  5 ßl  
were taken from the reaction tubes after a certain number of cycles, PCR 
products were separated on 1.6% agarose and stained with ethidium bro­
mide. GAPDH levels were very consistent in all samples, not warranting 
any further correction of mRNA values for the cytokine of interest.
Blood analysis
Mice were bled after ether anesthesia, and blood was collected in 2-ml 
EDTA Lubes, mixed well, and placed on 4°C. Thereafter, the levels of 
white blood cells, RBC, large unidentified cells, and hemoglobin and dif­
ferentiation of the white blood cells were determined on a cytometric an­
alyzer (Bayer/Technicon H2, Bayer, Tijdrecht, The Netherlands).
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Determination o f anti-col Ligen Abs
To investigate whether treatment of CIA with mIL-12 or anti-mIL-12 
changed CII-specific Ab subtypes, we determined subtype Ab liters. Abs 
against bovine CII were determined with an ELISA. The titers of total Igs, 
IgGlt and IgG2a were measured. Briefly, ELISA plates (Maxisorb, Nunc, 
Copenhagen, Denmark) were coated with 10 fig of bovine CII. Thereafter, 
nonspecific bindings sites were blocked with \%  BSA solution. Serial 1/10 
dilutions of the immune sera were added, followed by incubation with 
isotype-specific goat anti-mouse peroxidase ( l / l  000) and substrate (5-ami- 
nosalicylic acid). Plates were read at 492 nm.
Histology
Mice were killed by ether anesthesia. Thereafter, ankle and knee joints 
were removed and fixed for 4 days in 4% formalin. After décalcification in 
5% formic acid, the specimens were processed for paraffin embedding (26,
27, 36). Tissue sections (7 /xm) were stained with hematoxylin and eosin 
or Safranin 0 . Histopathologic changes were scored using the following 
parameters. Infiltration of cells was scored on a scale of 0 to 3, depending 
on the amount of inflammatory cells in the synovial cavity and synovial 
tissues. Proteoglycan depletion was determined using Safranin O staining. 
The Joss o f  proteoglycans was scored on a scale of 0 to 3, ranging from full 
stained cartilage to destained cartilage or complete loss of articular carti­
lage. A characteristic parameter in CIA is the progressive loss of articular 
cartilage. This destruction was separately graded on a scale of 0 to 3, 
ranging from the appearance of dead chondrocytes (empty lacunae) to 
complete loss o f the articular cartilage. Histopathologic changes in the knee 
joints were scored in the patella/femur region on five semiserial sections of 
the joint, spaced 70 /u,M apart. Scoring was performed on decoded slides by 
two observers, as described previously (26, 27, 36).
Statistical analysis
Differences between experimental groups were tested using the Wilcoxon 
rank test, unless stated otherwise.
Results
Role o f  IL-12 during the onset o f  CIA
DBA-1 Lac/J mice develop gradual onset of CIA after immuniza­
tion with CII in CFA, ranging from 30 up to 90% on day 70. Early 
expression of CIA can be enhanced with a single i.p. injection of 
40 jig of LPS at the time of onset on day 28 (Fig. 1 A), To inves­
tigate the involvement of IL-12 in this acceleration, mice without 
signs of CIA were selected on day 28 and challenged with LPS. 
Treatment with 200 ju,g of purified sheep anti-mIL-12 Abs on days
28, 30, and 32, starting shortly after LPS injection, highly reduced 
CIA expression (Fig. 1 A). Anti-mIL-12 treatment suppressed LPS- 
accelerated CIA expression to the level of onset of CIA in non­
treated DBA-1 Lac/J mice. To further underline the accelerating 
role of IL-12, daily treatment with 100 ng of mIL-12 was given 
from day 28 to day 32. Enhanced disease incidence was evident 
within a few days (Fig. 15).
In addition, we studied whether endogenous IL-12 is involved in 
the onset of CIA. As the onset of arthritis is rather variable in 
DBA-1 Lac/J mice, DBA-1 Bom mice were used, which normally 
show high arthritis incidence after CII immunization (80% inci­
dence on day 37; Fig. 2A). Treatment with 200 jug of purified 
sheep anti-mlL-12 Igs on days 28, 30, and 32 suppressed both 
disease incidence and arthritis score of CIA (Fig. 2, A and B). 
Subsequent studies were all performed with DBA-1 Bom mice.
Role o f  IL-12 in established CIA
To investigate the involvement of IL-12 in established arthritis, 
treatment with neutralizing anti-mIL-12 Abs was started on day 35 
and repeated on days 37 and 39. Unexpectedly, no suppression of 
arthritis severity was found. Instead, these mice showed an im­
pressive exacerbation of arthritis, starting a few days after cessa­
tion of anti-mIL-12 treatment and suggesting that endogenous con­
trol of arthritis was impaired by anti-mIL-12 treatment. This 
experiment was repeated, and synchronized data are shown in Fig-
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FIGURE 1. Role of IL-12 during the onset of accelerated and classic 
CIA in DBA-1 Lac/J mice. A, Immunized DBA-1 Lac/J mice without 
signs of CIA on day 28 were divided into three separate groups of at 
least 10 mice. One group of mice was not treated, and arthritis onset 
was monitored. The other groups were treated with 200  of sheep  
Igs or 200 /x g of sheep anti-mIL-12 Abs followed by LPS acceleration. 
B, Im m unized  DBA-1 Lac/j mice without signs o f  CIA were selected  
and divided into two separate groups of 10 mice. Mice were treated 
with either 100 ng of mlL-12 or 100 ng of BSA for 5 consecutive days. 
The data represent the m ean inc idence  o f  disease in two identical 
experiments.
ure 3. In a third experiment the degree of exacerbation was less. As 
can be seen in Table I, the severity of the arthritis was already high 
in this group, probably explaining the lack of exacerbation.
The exacerbation was confirmed with histology (Fig. 4). The 
number of inflammatory cells, in particular the relative number of 
granulocytes, was markedly increased. Cartilage damage was not 
significantly higher (Table II). Further proof of exaggerated dis­
ease was provided by enhanced IL-1 ß and TNF-a mRNA levels in 
the synovial tissue, whereas mRNA levels of IL-4, IL-10, IFN-7, 
and TGF-j3 were unchanged (Table III).
Treatment o f  established CIA with rmlL-12
Since neutralization of endogenous IL-12 caused a marked exac­
erbation of arthritis, we wondered whether late treatment might 
have a therapeutic effect. DBA-1 Bom mice with established CIA 
on day 35 were treated for 7 days with 100 ng of rmIL-12. This 
resulted in gradual suppression of arthritis, reaching significance
The Journal of Immunology 4097
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FIGURE 2. Effect of anti-mIL-12 treatment on the onset of CIA in 
DBA-1 Bom mice. Mice without expression of CIA were selected on 
day 28 after immunization with Cil and divided into two separate 
groups. Mice were treated with either 200 fig of sheep Igs or 200 fig 
of anti-mlL-12 Abs on days indicated by arrows. A, Incidence of CIA is 
expressed. B, Arthritis score is expressed. The data represent the mean 
incidence or the mean ± SD arthritis score of two experiments with at 
least 10 mice per group. * indicates p < 0.05, by Wilcoxon rank test, 
compared with the control group.
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FIGURE 3. Exacerbation of CIA after anti-mIL-12 treatment. DBA-1 
Bom mice with established CIA were selected on day 35 and divided 
into two separate groups of at least nine mice per group with roughly 
the same mean arthritis score. Anti-mIL-12 (200 /itg) or control Igs were 
injected i.p. as indicated by arrows. Data are expressed as the mean ±  
SD percentage of the control (sheep Igs) arthritis score of two experi­
ments (1 and II, see Table 1). * indicates p < 0.05, by Wilcoxon rank 
test, compared with the control group.
Table I. Exacerbation of CIA after anti-mIL-12 treatmenta
Expt. Group
Arthritis Score
PMN 
Influx 
tn Knee 
Joints6Day 35 Day 46 Day 52
1 Control 1,8 ± 0.8 2.0 ± 0.9 1.9 ± 1.1 3/18
Anti-mIL-12 1.8 ± 0.9 2.8 ± 1.2 3.5 ± 1.3 (185%)c 13/18
II Control 1.9 ± 1.2 2.8 ± 1.4 2.6 ± 1.1 6/26
Anti-mIL-12 2.0 ± 1.3 3.8 ± 1.4 4.2 ± 1.0 (179%) 20/26
HI Control 4.7 ± 1.2 4.2 ± 0.9 3.6 ± 0.7 14/18
Anti-mIL-12 4.6 ± 1.1 4.4 ±1.0 4,4 ±0.9 (121%) 15/18
*7 Mice with established CIA were selected at day 35 and divided into separate 
groups of at least nine mice with the same arthritis score. Three repeat experiments 
were performed. Sheep anti-mIL-12 Ab (200 /u,g) or control sheep Igs were injected 
at days 35, 37, and 39. In total, three identical experiments were performed.
b Jhe number of knee joints is expressed in which marked influx of PMNs 
was found in synovial tissues or joint cavity. More than 90% of the animals 
expressed arthritis in both knee and ankle joint of the same leg. PMN ~ poly­
morphonuclear leukocytes.
c Arthritis score expressed as percentage of the control at day 52.
on day 40 (Fig. 5). Histology taken on day 42 confirmed this sup­
pression, including a clear reduction in numbers of synovial infil­
trate and granulocytes. Intriguingly, apart from suppression of cel­
lular infiltrate, amelioration of both cartilage proteoglycan loss and 
cartilage surface destruction was noted (Fig. 6 and Table II).
To obtain insight into the mechanism of the IL-12-mediated 
suppression, mRNA levels were measured in synovial specimens. 
Levels of IL-lß, IL-IRa, and TNF-a were similar, IL-4 and 
TGF-ß were slightly enhanced, whereas IL-10 and IFN-7 were 
greatly enhanced in tissue of IL-12-treated compared with control 
mice. Of interest, IL-12 treatment also induced IL-12 up-regula- 
tion (Table III and Fig. 7).
Dominant role o f  IL-10 in IL-12-mediated suppression
Plasma levels of IL-10 and IFN-y were analyzed at the end of the 
7-day IL-12 treatment (Fig. 8), Both parameters were markedly
enhanced. To further underline the potential involvement of IL-10 
up-regulation in the IL-12-mediated suppression, a final experi­
ment was performed in which animals were treated with IL-12 as 
well as anti-mIL-10 Abs (Fig. 9). That study again confirmed the 
clear suppression of established arthritis with IL-12 treatment and, 
furthermore, made it clear that concomitant anti-mIL-10 treatment 
completely prevented the IL-12 effect. Histology of these groups 
showed suppression of inflammation only in the 3L-12-treated 
mice (data not shown).
Anti-collagen type II A b  titers and circulating leukocytes
Involvement of shifts in anti-collagen type II Ab titers in exacer­
bations or suppressions of CIA seems unlikely. Anti-CII Ab levels 
are already high on day 35 of CIA, and neither mIL-12 nor anti- 
mIL-12 treatment caused major changes in the levels of anti-CII 
IgGs, IgGl, or IgG2A (data not shown).
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FIGURE 7. PCR analysis of synovial tissue, Synovium biopsies of six 
mice per experimental group were pooled, and RNA was extracted, 
PCR was performed as described in Materials and Methods. Animals 
with established CIA were treated i.p, for 7 days with 100 ng of BSA or 
100 ng of mlL-12, started on day 35 (see Fig. 5). Note the enhanced 
synovial mRNA expression of IFN-y, IL-10, and IL-12 after IL-12 
exposure.
ARTHRITIS SCORE
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FIGURE 9. Abrogation of the suppressive effect of IL-12 treatment on
established CIA by coadministration of anti-mIL-10 Abs, DBA-1 Bom 
mice with established CIA were selected on day 33 and divided into 
four separate groups of 10 mice. Control mice received daily i,p, BSA 
(100 ng) and rat Igs (0.75 mg) as indicated by arrows. The IL-12 group 
was injected with 100 ng of mlL-12 and rat Igs as indicated by the 
arrows. The mlL-12/anti-IL-10 group received mlL-12 and anti-mIL-10 
(0.75 mg), The anti-mIL-10 group was injected with BSA and anti-mlL- 
10. * indicates p  < 0.05, by Wilcoxon rank test, compared with the 
control.
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FIGURE 8. Plasma levels of IL-10 and IFN-y after IL-12 treatment. 
Mice with full-blown CIA were treated for 7 days with either BSA 
(controls) or mlL-12 started on day 35 (see Fig. 5). Mice were bled on 
day 42, and plasma levels of IL-10 and ]FN-y were determined by 
ELISA. Values are expressed as the mean ± SD cytokine level of six 
mice per group of two experiments, * indicates p  < 0,05, by Wilcoxon 
rank test, compared with the control.
treatment. Recent in vitro studies confirm the strong capacity of 
IL-12 to induce IL-10 production by both T cells and monocytes 
(17-21), Furthermore, IL-12 inhibits IL-4 and IL-10 production in 
allergen-specific T cells, but this effect was not noted in already 
activated T cells (17). IL-12 does not suppress a Th2 cell recall 
response (51). Intriguingly, IL-12 exacerbates, rather than sup­
presses, Th2-dependent pathology in IFN-y knockout mice in the 
absence of endogenous IFN-y (52),
Our data show that IL-12 enhances the onset of arthritis, prob­
ably related to enhanced IFN-y and nitric oxide production and
subsequent generation of TNF and IL-1. In late disease, IL-12 
up-regulates itself as well as IL-10 and IFN-y, without significant 
effects on IL-1 and TNF. Suppression of arthritis is probably due 
to IL-10, although it cannot be excluded that IFN-y plays a role in 
this as well. Earlier studies in arthritis models showed variable 
effects of IFN-y, with a tendency for suppression in established 
disease. It is known that repeated high dose IL-12 (1 /xg/day) treat­
ment may have unwanted side effects on bone marrow and lymph 
nodes. We have not seen such effects using daily treatment with 
100 ng. Leukocyte counts in the blood were normal; the only 
change was some up-regulation of large unidentified cells, proba­
bly reflecting lymphoblasts.
The present study confirms a role for IL-12 in arthritis onset and, 
furthermore, identifies a regulatory role in late disease. It is now 
well accepted that TNF and IL-1, in particular, are key therapeutic 
targets in the treatment of human RA (53). Trials with anti-TNF 
provide great relief of symptoms, yet data on protection against 
ongoing cartilage destruction are under investigation. Trials with 
IL-IRa are ongoing (54), and it is promising to see first data show­
ing protection against joint erosions. In addition, new trials in RA 
patients are in progress with IL-4 and IL-10, focusing on the ex­
pected benefit of IL-1/TNF inhibition and additional up-regulation 
of cytokine and enzyme inhibitors as well as immunomodulation 
of RA orchestrating, with as yet unidentified Thl responses. IL-12 
would be a challenging target, with expected protection against 
onset or acute exacerbation of chronic arthritis upon IL-12 block­
ing. IL-12 has been detected in synovial fluid cells of RA patients 
(55). Moreover, recent studies in a murine arthritis, caused by Bor­
relia burgdorferi, showed a reduction in severity of arthritis with 
anti-IL-12 treatment (56).
Analysis of immune-mediated tissue injury in atherosclerotic 
plaques demonstrated that the degree of destruction is dependent 
on the critical balance of IL-12 and IL-10 (57). The present study 
urges great care with IL-12 elimination in established arthritis
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linked to potential impairment of IL-10-mediated control. It is 
tempting to speculate that a combination treatment of anti-IL-12 
with supplementation of IL-10 may provide optimal impact, but 
further insight into the regulation of IL-10/IL-12 balance in vari­
ous stages of the disease is highly warranted.
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